ABBVIE
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Effect of Long-term Psoriasis on Patients' Life - CORONATE
- Conditions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 543
- Registration Number
- NCT05555953
- Locations
- ๐ฎ๐น
AZIENDA USL TOSCANA CENTRO - Piero Palagi /ID# 245569, Florence, Firenze, Italy
๐ฎ๐นOspedale San Martino /ID# 245641, Genoa, Genova, Italy
๐ฎ๐นPoliclinico Agostino Gemelli /ID# 245570, Rome, Roma, Italy
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05538585
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami /ID# 249531, Miami, Florida, United States
๐บ๐ธAcpru /Id# 249532, Grayslake, Illinois, United States
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05530278
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials LLC /ID# 248824, Anaheim, California, United States
๐บ๐ธClinical Pharmacology of Miami /ID# 248823, Miami, Florida, United States
๐บ๐ธPPD Clinical Research Unit -Las Vegas /ID# 248853, Las Vegas, Nevada, United States
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT05513703
- Locations
- ๐ซ๐ท
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267, Bron, Rhone, France
๐ฆ๐บMonash Medical Centre /ID# 247679, Clayton, Victoria, Australia
๐ซ๐ทCHU Lille - Hรดpital Albert Calmette /ID# 246263, Lille, Hauts-de-France, France
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 114
- Registration Number
- NCT05512390
- Locations
- ๐บ๐ธ
University of Nebraska Medical Center /ID# 246715, Omaha, Nebraska, United States
๐ฆ๐บConcord Repatriation General Hospital /ID# 249240, Concord, New South Wales, Australia
๐บ๐ธUniversity of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona, United States
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 461
- Registration Number
- NCT05507580
- Locations
- ๐ฎ๐น
Azienda Ospedaliera di Perugia /ID# 246632, Perugia, Umbria, Italy
๐จ๐ฆDermatology Research Institute - Blackfoot Trail /ID# 246703, Calgary, Alberta, Canada
๐ง๐ฌMedical center Cordis /ID# 253310, Pleven, Bulgaria
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 90
- Registration Number
- NCT05496335
- Locations
- ๐บ๐ธ
The Eye Research Foundation /ID# 244430, Newport Beach, California, United States
๐บ๐ธDeNova Research /ID# 244421, Chicago, Illinois, United States
๐บ๐ธBellaire Dermatology Associates /ID# 244428, Bellaire, Texas, United States
Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
- Conditions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 400
- Registration Number
- NCT05496348
- Locations
- ๐ฉ๐ช
St. Marien- und St. Annastiftskrankenhaus /ID# 273172, Ludwigshafen am Rhein, Rheinland-Pfalz, Germany
๐ฆ๐นKepler Universitaetsklinikum GmbH /ID# 251868, Linz, Oberoesterreich, Austria
๐ฆ๐นKrankenhaus der Barmherzigen Brueder Wien /ID# 251867, Vienna, Wien, Austria
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
- Conditions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT05494606
- Locations
- ๐ฌ๐ท
University General Hospital of Alexandroupoli /ID# 270159, Alexandroupoli, Evros, Greece
๐ฎ๐นAzienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 260811, Rome, Roma, Italy
๐ฎ๐นFondazione Policlinico Universitario Agostino Gemelli IRCCS-Universitร Cattolica /ID# 260946, Rome, Roma, Italy
A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 32
- Registration Number
- NCT05486195
- Locations
- ๐ง๐ช
Centre for Clinical Pharmacology, UZ Leuven, Leuven, Belgium